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Abstract: 
Currently no published data addressing the burden of Human Immunodeficiency Virus (HIV) and Hepatitis B 
Virus (HBV) co-infection among injecting drug users (IDUs) in Kenya exists. These two viruses share similar 
routes of transmission, with illicit drug use by injection being the major route of infection. Injecting drug use is a 
rapidly growing problem in coastal towns of Kenya and the problem is aggravated by sex tourism.This study 
aimed at determining the prevalence of HBV in HIV positive IDUs and correlating the findings with socio-
demographic factors of the study population.A cross-sectional study was conducted using structured 
questionnaires and laboratory testing of blood samples. Surface antigens for HBV (HBsAg) and anti-HIV 
antibodies were screened using rapid kits followed by Enzyme Linked Immunosorbent assay tests on positive 
samples using Hepanostika and Vironostika test kits, for HIV and HBV, respectively. The CD4+ T-cell count 
was determined by flow cytometry.The prevalence of HIV/HBV co-infection was 14.3% (13/91) with a mean 
age of 33.2 (SD ± 8.1) years. The mean CD4+ cell count in the HIV/HBV co-infected individuals was 
significantly lower than HIV mono-infection. Needle sharing and duration of active injection of drugs were 
significantly associated with HIV/HBV co-infections.This study concludes a potentially high prevalence of 
HBV/ HIV co-infection in injecting drug users in Malindi, Kenya. With limited evidence on IDU prevalence and 
its consequences in sub-Saharan Africa, the results of this study highlight the need for a more refined policy on 
HIV treatment strategy among IDUs. There is a further need for triple testing for HIV, HBV and HCV among 
suspected IDUs and other associated risk groups like the commercial sex workers before commencement of 
treatment. 
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1. Introduction 
There is still limited data on the true rate of illicit injecting drug use (IDU) in sub-Saharan Africa. It is however 
estimated that Kenya, Mauritius, and South Africa combined record an estimated 300-350,000 IDUs (Mathers et 
al., 2008) 
Most IDUs stand a high risk of contracting human immunodeficiency virus (HIV), hepatitis C virus 
(HCV) and hepatitis B virus (HBV) (Aceijas et al., 2004). Due to shared routes of transmission, there is also an 
increased risk of co-infection with the three disease agents, but especially HIV/HBV co-infection due to their 
relatively high prevalence rates compared to HCV. HIV infections among IDUs have been documented 
worldwide (Mathers et al., 2008, Dewing et al., 2004, McCurdy 2006). The few similar studies done in Kenya 
have reported a variation in the prevalence rates from one region to another (Mathers et al., 2008, Odek-Ogunde 
et al., 2004, Odek-Ogunde et al., 2012). 
HIV infection among IDUs has constantly been on the rise within the Kenyan coast (Beckerleg et al., 
2005) where an estimated 17% of new HIV infections are within this group (Nieburg et al., 2011). It is however 
notable that limited information on the rates of HBV mono- and HIV/HBV co-infections within this population 
of IDUs exists for this region. In Malindi, a tourist town within the Kenyan coast and reported to have a very 
high number of drug injecting population (Nieburg et al., 2011), no studies have been conducted to document the 
true prevalence of HBV mono- or HIV/HBV co-infections. It is notable that a rise in IDUs in this town could 
partly be aggravated by the rising sex tourism. HIV/HBV co-infection changes the natural course of either HIV 
or HBV disease leading to adverse effects. Resistance to treatment by either of the viruses could greatly affect 
the outcome of the treatment of the other, and ultimately the spread of the diseases within the population could 
have a detrimental public health effect. It is thus necessary to establish the rates of HIV/HBV co-infections so as 
to aid in designing and implementing appropriate and specific intervention strategies. In this study, we report the 
results of a cross-sectional study, conducted to estimate the prevalence of HBV mono-, and HIV/HBV co-
infections among IDUs in Malindi district in Kenya. 
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2.0 Materials and Methods 
2.1 Study design 
This was a cross-sectional study involving consenting adult IDUs from Malindi district in Kenya. 
 
2.2 Study site and population 
This study was carried out within the confines of a drug rehabilitation program in Malindi district, along the 
Kenyan coast. Currently referred to as Malindi sub-county, Malindi is a major tourist destination in Kenya 
attracting tourists from all over the world but mainly from Germany, Italy and Britain. The town is situated north 
of Mombasa, along Indian Ocean and west of Lamu, another major tourist destination. The town is cosmopolitan 
with the major religion being Islam. 
 
2.3 Sample collection 
The consenting participants to this study were interviewed using structured questionnaires to collect information 
on socio-demographic characteristics. Information on behavioral risk factors included the duration of active 
injecting drug use, number of times the needle was shared, engagement in commercial sex work (CSW) and men 
having sex with other men (MSM). 
Eventually, 5 mL of venous blood was collected for use in serological screening for HIV and HBV, as 
well as for CD4 T lymphocyte counts. Any non-responsive or uncooperative participant was excluded from the 
study. 
 
2.4 Serological screening for HIV and HBV 
Testing for HIV antibodies and HBV surface antigen (HBVsAg) was carried out using rapid tests and ELISA 
assay platforms. Screening for HIV infection was done as recommended by the revised Kenya National 
guidelines (NASCOP 2008). Colloidal Gold Kit which detects anti-HIV IgG antibodies was used as the initial 
test. Samples reactive in this first test were re-tested using a second antibody test, the First Response Kit, 
(Shanghai Kehua Bio-engineering Co., Ltd., China). 
Indeterminate results were confirmed using the Vironostica HIV ELISA (Wantai Biological Pharmacy 
Enterprise Co., Ltd, Beijing, China) as a tie breaker. Screening for HBVsAg was done using the KEMRI 
HEPCELL kit and confirmed using the Hepanostika HBV ELISA kit (Shanghai Kehua Bio-engineering Co., Ltd., 
China). All testing was done according to manufacturers’ instructions. Those samples which tested positive for 
both HIV and HBV were considered to be HIV/HBV co-infected. CD4+ T-cell count was determined by flow 
cytometry. 
 
2.5 Ethical clearance 
The study was approved by the ethical committee of the Kenya Medical Research Institute, ERC number 2444. 
Participation was voluntary and total confidentiality was observed. HIV and or HBV status was only 
communicated back to the clinicians for purposes of clinical interventions and management. 
 
2.6 Data analysis 
Data was analyzed using SPSS for windows (Version 16.0, 2007, SPSS Inc, Chicago, IL, USA). 




3.1 Baseline characteristics of IDU participants 
In total 91 (49 male and 42 female) IDUs were recruited. The mean age recorded was 33.2 (SD ± 8.1) years 
(Table 1), where 34.0% (31) were aged below 29 years, 47.3% (43) between 30 – 39 years, 16.5% (15) between 
40-49 years and 2.2% (2) were aged between 50-60 years (Table 2). 
Table1. The prevalence of HIV/HBV co-infection and the estimated CD4+ T-lymphocyte count among the 
intravenous drug users in Malindi 





P        HIV HBV HIV/HBV 
         Prevalence {n}(%)   91(100.0) 49(53.8) 42(46.2) 91(100.0) 13(14.3) 13(14.3) 
         Age(yrs) mean(SD)  33.2(±8.1) 35.29(±8.3) 30.29(±6.9) 0.001* 33.2(±8.1) 33.58(±7.35) 33.58(±7.35) 
         CD4+T cell count  
                mean(SD) 530.9(±405.1) 461(±326.4) 0.388 495.5(±366.5) 171.3(±94.4) 171.3(±94.4)* 
         HIV (%) 49/49(100.0) 42/42(100.0) 0.018 
         HBV (%) 7/91(7.7) 6/91(6.6)  
         HIV/HBV (%) 7/49 (14.3) **  6/42 (14.3) **   
 
      *a significantly reduced CD4+ T-lymphocyte count compared to HIV mono-infection (p=0.001) 
     ** shows prevalence of HIV/HBV co-infection within the individual groups 
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3.2 Prevalence of HBV infection and HIV/HBV co-infection 
As shown in table 1, the prevalence of HIV/HBV co-infection in the male population was 7.7% (7/91) of the 
male participants and 6.6% (6/91) of the female. However, within the specific groups of the HIV infected IDUs, 
HBV accounted for 14.3% in each case. Although the mean CD4+ T-cell count in all the HIV infected was 
approximately 496 cells/µL, there was a significantly low CD4+ T-cell count for the HIV/HBV co-infected, 
accounting for only 171 cells/µL of blood compared to the HIV mono-infected (p=0.001). 
 
3.3 Behavioral factors that aggravate transmission 
Analysis of behavioral characteristics that aggravate HIV/HBV transmission as shown in table 2 revealed that 
only 90.4% (47) of the 52 respondents in this category were strict IDUs. Another 
1.9% (1/52) was both an IDU and MSM, while the remaining 9.6% (5/52) were confirmed to be both 
IDUs and CSW. Although strict IDUs accounted for the highest number of HIV infections compared to the other 
2 groups, the difference was not significant (p=0.809). On the other hand IDU-MSM and IDU-CSW 
combinations were at a higher risk of HIV/HBV (p=0.001) co-infection compared to strict IDUs. Further those 
who shared needles with more than 2 partners also recorded a higher risk HIV/HBV co-infections (p=0.001). 
Based on the duration of needle use, participants who responded to injecting for more than 10 years were 
associated with high rate co-infections (p=0.000). 
Table 2: Table 2: Prevalence of HIV/HBV co-infection within the different groups and clusters assessed 
Characteristics Total HIV P HIV/HBV P 
n(%) n(%) 
Age groups N=91 0.776 0.206 
≤29 31(34) 3(23) 
30-39 43(47) 8(61) 
40-49 15(16) 1(8) 
≥50 2(3) 1(8) 
Total 91(100) 13(100) 
Sex N=91 0.357 0.969 
F 42(46) 6(46);(14)** 
M 49(54) 7(54);(14)** 
Total 91(100) 13(100) 
Marital status N=52 0.829 0.004* 
Single 47(90) 13(100);(28)**  
Married 3(6) 0(0.0) 
Divorced 2(4) 0(0.0) 
Total 52(100) 13(100) 
Level of education N=52 0.697 0.004* 
Primary 37(71) 9(69);(24)**   
Secondary 12(23) 4(31);(33)** 
College 3(6) 0(0.0) 
Total 52(100) 13(100) 
Risk behaviors N=52 0.809 0.030 
IDU 46(89) 9(69);(20)** 
IDU,FCSW 5(9) 3(23);(60)**  
IDU,MSM 1(2) 1(8) 
Total 52(100) 13(100) 
Number of partners sharing needle N=52 0.158 0.000* 
< 1 1(2) 0(0.0) 
1-2 37(71) 0(0.0) 
> 2 14(27) 13(100);(93)**  
Total 52(100) 13(100) 
Duration of needle use (years) N=52 0.274 0.000* 
< 10 19(36) 0(0.0) 
10-20 27(52.0) 8(62);(30)** 
> 20   6(12) 5(38);(83)**  
Total 52(100.) 13(100) 
** The rates within individual clusters. * statistically significant. 
FCSW – Female Commercial sex worker; MSM – Men having sex with Men, IDU-Injecting Drug Users 
  
3.4 Co infection with HBV/HIV and age 
The IDUs aged between 30 and 39 years recorded the highest rate of HIV/HBV co-infection whereas IDUs 
above 50 years showed the lowest rate {7.7% (1/13) (p=0.000)} and the least infection rate in all categories 
(Table 2) 
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3.5 HIV/HBV co-infections and marital status 
Assessment of the marital status showed that 90.4% (47/ 52) of the HIV infected participants were single, 5.8% 
(3/52) married and 3.8% (2/52) divorced. Co-infection of HIV and HBV was only observed (100%) among the 
cluster of participants of the “single” status, contributing to approximately 28% (13/47) within of all the HIV 
infected IDUs within this cluster. 
 
3.6 HIV/HBV co-infections and the level of education 
Those participants with only basic primary education accounted for 71% (37 /52), with the least being those with 
tertiary education accounting for 5.8% (3/52). Of the HIV/HBV co-infected patients, once again those with the 
basic primary education accounted for 69% (9/13) with the remaining 31% (4/13) being individuals with 
secondary education. However, within the cluster of those with primary education, only 24% (9/37) as opposed 
to the 33% (4/12) of those with secondary education were co-infected. HIV/HBV HIV infected individuals in 
this study with tertiary education had no co-infection with HBV 
 
4. Discussion 
Different African countries have embarked on intensive public health measures for the prevention of 
transmission of HIV within and outside the “hard to reach” populations such as intravenous drug users. With the 
availability of anti-retroviral therapy for HIV and the fact that infection by HBV and its subsequent resistance to 
therapy could change the course of HIV treatment, there is a need for a clear data on the HIV/HBV co-infections. 
In this study we report a prevalence of 14.3% for HIV/HBV co-infection among active IDUs in this 
sub-county within the Kenyan coast. The prevalence rate reported in this study was higher than 6% rate of 
HIV/HBV co-infections previously reported for Kenya (Muriuki et al., 2013, Harania et al., 2008). This finding 
of a higher prevalence was however expected since as opposed to the previous studies which were within the 
general population of HIV sero-positive patients, this study targeted a high risk population. The implication of 
the three findings in Kenya strengthens the need for a more defined policy on the treatment strategy for the high 
risk population infected with HIV. We note that apart from exposure to risky behaviours potentially exposing our 
cohort to multiple co-infections, the dynamic life style of our cohort would literally expose them as well to high 
default rate on treatment. Although not having been part of this study, it is would also be interesting to assess the 
resistance patterns to the current HIV and HBV treatment regimen. 
When compared to HBV mono-infection, the prevalence in this study was once again higher compared 
to HBV mono-infection among the IDUs previously reported at 4.5% (Odek-Ogunde et al., 2004), an indication 
that hepatitis infection in HIV-infected persons may be higher than that of the general population. 
On behavioral characteristics that aggravate HIV/HBV co-infection transmission, the fact that IDU-
MSM and IDU-CSW showed a significantly higher risk of transmission presents a major public health concern. 
The legal and the cultural factors associated with MSM and CSW further aggravates the risk of infection and co-
infection. Apart from engaging in the two practices when under intoxication, the two groups also fail to seek 
medical intervention in cases of infections for fear of arrest and rebuttal from the local community. It suffices to 
note that these 2 groups of MSM and female CSW provide a link of transmission of the viruses from the circle of 
IDUs to the general population. Further, Malindi, just as other towns in the coastal Kenya, being a sex tourism 
town, there is a potential for further transmission across the border, with countries standing at a risk of cross 
border transmission mainly being in Europe. This therefore calls for continuous monitoring of these two 
categories in terms of potential sexually transmissible infections, intense harm reduction strategies such as “one 
syringe-one needle”, advocacy of condom use mainly to the potential clients like the revelers and tourists and 
molecular surveillance of circulating genotypes of HIV and HBV in the region. At present, harm reduction 
strategy remains paramount to ensure a reduction in risky practices such as sharing needles and syringes. 
Results obtained from the assessment of the marital status and the levels of education strengthen the 
assertion that high levels of poverty contribute significantly to transmission of diseases. The fact that co-
infection was not found among those with tertiary education and low within the married, points to the fact that 
these two categories command some sense of responsibility and self sustenance thus reducing the risks of 
sharing needles as well as involving in sex for commercial purposes. This assertion can further be strengthened 
by the fact that compared to similar studies done, lower prevalence were reported in China (0.3%), USA (7%) 
and France (8%) (Zhou et al., 2012, Weinbaum et al., 2008, Larsen et al., 2004), as opposed to the high 
prevalence in this study. We however acknowledge that the HIV prevalence of 6% in Kenya´s general 
population (NACC 2014) cannot be underestimated to contribute to the differences in prevalence in the studies 
cited. Increased risk of transmission through sharing or long term use of needles among IDUs has well been 
elucidated in various studies (Zhou et al., 2012, Zarocostas 2011, Zhou et al., 2011). 
Further, the influx of sex tourists in this region is cannot be underestimated as a factor that aggravates 
the problem of IDUs. Sex tourism promises easy money to this group, both in heterosexual, homosexual or both. 
Although not included in this study, our preliminary findings showed that a significant number of participants 
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engage in these sexual orgies under intoxication, leading to a high number of sexual clients per night and failure 
to use protective measures like condoms. The risk to health is not only exportation of the local strains of the 
viruses, but also importation of the foreign viral strains not known to circulate within the region. 
Of interest in this study is the fact that the HBV prevalence in our finding among this group is similar 
to those already recorded by some other regions in south Asia, like Bangladesh (9.4%), India (10.2%) and Iran 
(17.3%) where illicit drug use is also an acknowledged problem (Nelson et al., 2011, Rahimi-Moraghar 2015). In 
comparison to some western countries like France (4.8%), Germany (7.2%), United Kingdom (8.9%) (Nelson et 
al., 2011) and USA (11%) (Weinbaum et al., 2009), our finding of 14% is high. Our findings of prevalence 
above those in the western countries within the population of IDUs is of special importance, since it shows that 
contrary to the popular belief that HBV infection in Africa mainly appears in early childhood (Barth et al., 2010), 
and that IDU is less influential in transmission compared to the western countries (Cooper et al., 2009, Lavanchy 
2004, Modi 2007) there seem to be a dramatic shift, and transmission by IDU is currently surpassing those seen 
in the western countries. 
  
5. Conclusion 
In conclusion, different studies have documented the burden of HIV, HBV and HBV co-infections among IDUs 
(Zhou et al., 2012, Zarocostas 2011, Zhou et al., 2011) in different parts of the world. We have however, not 
found any data documenting the burden of HIV/HBV co-infection within Malindi, a county with the highest 
illicit drug use in Kenya and a hub for international sex tourism. To the best of our knowledge therefore, this is 
the first study assessing and documenting the burden of HIV/HBV co-infection within this region. The high 
prevalence determined within this high risk group is of special importance to intervention strategies by the 
different stakeholders, both local and international. We have further managed to show in our study group, the 
burden of other risk factors (such as MSM and CSW) associated with illicit intravenous drug use. 
A major limitation of this study is the fact that it was mainly carried out in a cohort of the IDUs 
undergoing rehabilitation, hence the data on all IDUs in the general population is not captured in this study. This 
is important especially taking into consideration that the behavior patterns for the two groups may be different as 
a result of the rehabilitation process. Further, MSM and CSW in the general population away from illicit drug 
use were not tested for further comparison. 
Therefore the results of this study remain only limited HIV/HBV co infections within the IDU 
population. 
We further recommend the need for molecular surveillance of the circulating strains of these viruses, 
treatment and resistance profiles of the drugs in use, and a further investigation of the 
IDUs outside the rehabilitation program as well as non IDUs who engage other high risk behaviors 
such as CSW and MSM in order to get the true prevalence of the co-infections. 
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